Article info
Clinical and epidemiological research
Extended report
Clinical efficacy of leflunomide in primary Sjögren's syndrome is associated with regulation of T-cell activity and upregulation of IL-7 receptor α expression
- Correspondence to Dr J A G van Roon, Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Heidelberlaan 100, F02.127, Utrecht 3584 CX, The Netherlands; J.vanRoon{at}umcutrecht.nl
Citation
Clinical efficacy of leflunomide in primary Sjögren's syndrome is associated with regulation of T-cell activity and upregulation of IL-7 receptor α expression
Publication history
- Accepted March 23, 2012
- First published May 6, 2012.
Online issue publication
October 25, 2017
Article Versions
- Previous version (25 October 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions